Remdesivir has ‘no meaningful impact’ on COVID-19 survival, huge study finds

The antiviral drug remdesivir does not reduce deaths among COVID-19 patients, as compared with standard care, according to the results of a large, international trial.

The Food and Drug Administration, in May, authorized remdesivir to be used in an emergency to treat COVID-19, after a large clinical trial suggested that the drug reduces the time it takes for COVID-19 patients to be discharged from the hospital, as compared with a placebo treatment, Live Science previously reported. As of August, the drug has been authorized for use in all patients hospitalized with COVID-19, not only those on supplemental oxygen, The New York Times reported. Thousands of U.S. patients have received the treatment, including the president.

Source link

#Remdesivir #meaningful #impact #COVID19 #survival #huge #study #finds